Itrarite 100 Capsule contains Itraconazole 100 mg, a broad-spectrum antifungal agent belonging to the triazole class, indicated for the treatment of various systemic and superficial fungal infections. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a key component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itrarite 100 is commonly prescribed for infections such as aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis, including oropharyngeal and esophageal forms. The capsule formulation allows for convenient oral administration with improved bioavailability when taken with food. Dosage and duration of therapy depend on the severity and type of infection, as well as patient-specific factors. Caution is advised in patients with hepatic impairment or congestive heart failure, and potential drug interactions should be carefully evaluated due to itraconazole’s inhibition of cytochrome P450 enzymes. Common adverse effects include gastrointestinal disturbances, headache, and rash. Liver function tests and clinical monitoring are recommended during prolonged therapy to ensure safety and efficacy. Itrarite 100 Capsule should be used under medical supervision to optimize therapeutic outcomes.